Arrowhead to Present at Upcoming Conferences
PASADENA, Calif. -- November 7, 2013
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that it will present
data on the Dynamic Polyconjugate (DPC) siRNA delivery technology at two
upcoming scientific conferences.
Scheduled conference presentations include the following:
EuroTIDES 2013 – Prague, Czech Republic, November 13-14
November 14, 2013 – An oral presentation titled, “DPC technology for delivery
of therapeutic siRNAs,” will be presented by David Lewis, Ph.D., Chief
Oligonucleotide & Peptide Based Therapeutics Congress – San Diego, CA, USA,
November 19, 2013 – An oral presentation titled, “Targeted delivery of
therapeutic siRNAs using DPC technology,” will be presented by David Lewis,
Ph.D., Chief Scientific Officer.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and obesity and partner-based programs in oncology.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company’s email list to receive
news directly, please send an email to email@example.com
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Press spacebar to pause and continue. Press esc to stop.